A Phase I Study of GDC-0919 for Adult Patients With Recurrent Advanced Solid Tumors

Trial Profile

A Phase I Study of GDC-0919 for Adult Patients With Recurrent Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs Navoximod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Genentech; NewLink Genetics Corporation
  • Most Recent Events

    • 10 May 2017 According to a NewLink Genetics media release, data from this study will be presented at the 2017 ASCO Annual Meeting.
    • 02 Feb 2017 Status changed from recruiting to completed.
    • 01 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top